Principal Financial Group Inc. Has $14.21 Million Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR)

Principal Financial Group Inc. lowered its stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 478,864 shares of the company's stock after selling 23,993 shares during the quarter. Principal Financial Group Inc. owned approximately 0.96% of Immunocore worth $14,208,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. bought a new stake in Immunocore during the 4th quarter worth about $25,000. Oppenheimer Asset Management Inc. bought a new position in shares of Immunocore in the 1st quarter valued at about $225,000. NEOS Investment Management LLC boosted its stake in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after purchasing an additional 1,102 shares during the last quarter. Tema Etfs LLC bought a new position in shares of Immunocore in the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC boosted its stake in shares of Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock valued at $340,000 after purchasing an additional 3,238 shares during the last quarter. Institutional investors own 84.50% of the company's stock.

Immunocore Stock Down 1.2%

IMCR stock traded down $0.43 during mid-day trading on Friday, hitting $35.02. 178,525 shares of the company were exchanged, compared to its average volume of 344,517. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.31 and a current ratio of 6.36. The firm has a market cap of $1.76 billion, a P/E ratio of -81.44 and a beta of 0.77. The firm's 50 day simple moving average is $32.71 and its 200 day simple moving average is $30.60. Immunocore Holdings PLC Sponsored ADR has a 1-year low of $23.15 and a 1-year high of $41.54.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The business's quarterly revenue was up 33.6% on a year-over-year basis. During the same period last year, the company posted ($0.49) EPS. On average, sell-side analysts predict that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on IMCR. Mizuho reduced their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Wall Street Zen raised shares of Immunocore from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a "buy" rating and a $65.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, June 2nd. Finally, Oppenheimer increased their price target on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and an average target price of $58.89.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.